A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance - PubMed (original) (raw)
. 2022 Sep;77(3):632-641.
doi: 10.1016/j.jhep.2022.03.032. Epub 2022 Apr 7.
Si Hyun Bae 1, Heechul Nam 1, Hae Lim Lee 1, Sung Won Lee 1, Sun Hong Yoo 1, Myeong Jun Song 1, Jung Hyun Kwon 1, Soon Woo Nam 1, Jong Young Choi 1, Seung Kew Yoon 1, Jeong Won Jang 2
Affiliations
- PMID: 35398462
- DOI: 10.1016/j.jhep.2022.03.032
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance
Hyun Yang et al. J Hepatol. 2022 Sep.
Abstract
Background & aims: After hepatitis B surface antigen (HBsAg) seroclearance, the risk of hepatocellular carcinoma (HCC) remains, and the optimal surveillance strategy has yet to be determined. Herein, we aimed to evaluate incidence and risk factors for HCC and establish a novel prediction model for HCC development after HBsAg seroclearance.
Methods: A total of 1,443 patients with chronic hepatitis B who achieved HBsAg seroclearance between 1991 and 2020 were retrospectively screened for study eligibility. The data from 831 of these patients were included in the final analysis. A prediction model was developed based on multivariable Cox models. Harrell's C-index and a time-dependent AUROC were used for discrimination. Bootstrap analysis was performed for internal validation.
Results: Overall, 40 patients (4.8%) developed HCC after HBsAg seroclearance during a follow-up of 4,644 person-years (0.86%/year). Age at HBsAg seroclearance, presence of cirrhosis, family history of HCC, and more-than-moderate alcohol consumption were independently predictive of HCC, and these 4 independent variables were used to develop the prediction model. The C-index of the model was 0.804. The time-dependent AUROCs of the score for HCC prediction at 5, 10, and 15 years were 0.799, 0.835, and 0.817, respectively. The score also showed good discrimination in the internal validation and sensitivity analysis.
Conclusions: The novel prediction model based on age, cirrhosis, family history of HCC, and alcohol consumption enables reliable risk estimation of HCC after HBsAg seroclearance and may serve as a useful reference for decision-making in HCC surveillance for HBsAg-cleared patients.
Lay summary: After spontaneous hepatitis B surface antigen (HBsAg) seroclearance, the risk of hepatocellular carcinoma (HCC) remains. Age at HBsAg seroclearance, presence of cirrhosis, family history of HCC, and more-than-moderate alcohol consumption were independently associated with HCC development after HBsAg seroclearance. The novel prediction model using these 4 variables enables reliable risk estimation of HCC and serves as a useful reference for decision-making in HCC surveillance and management for HBsAg-cleared patients.
Keywords: Chronic hepatitis B; HBsAg seroclearance; Hepatocellular carcinoma; Prediction model.
Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
- A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations.
Tang Y, Chen Y, Chen HN. Tang Y, et al. J Hepatol. 2022 Dec;77(6):1722-1724. doi: 10.1016/j.jhep.2022.05.032. Epub 2022 Jun 9. J Hepatol. 2022. PMID: 35690263 No abstract available. - Reply to: "A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations".
Yang H, Bae SH, Jang JW. Yang H, et al. J Hepatol. 2022 Dec;77(6):1724-1725. doi: 10.1016/j.jhep.2022.08.026. Epub 2022 Sep 2. J Hepatol. 2022. PMID: 36058364 No abstract available. - A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?
Carlson S, Vaz K, Peterson A. Carlson S, et al. J Hepatol. 2023 Oct;79(4):e154-e155. doi: 10.1016/j.jhep.2023.01.021. Epub 2023 Feb 1. J Hepatol. 2023. PMID: 36736735 No abstract available. - Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?'.
Yang H, Kim JH, Han JW, Lee SK, Jang JW. Yang H, et al. J Hepatol. 2023 Oct;79(4):e155-e157. doi: 10.1016/j.jhep.2023.06.005. Epub 2023 Jun 27. J Hepatol. 2023. PMID: 37385474 No abstract available. - A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!
Lu W. Lu W. J Hepatol. 2024 Jun;80(6):e267-e268. doi: 10.1016/j.jhep.2023.09.016. Epub 2023 Oct 4. J Hepatol. 2024. PMID: 37797791 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical